Fundraising FoxLilly Asia Ventures — 2022 Investments
3 investments dated 2022 · listed companies and verified rows first · show all
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers.
BiotechHealthtechMedical DevicesNewtown Square, US
Zhengbin (Bing) Yao(Executive Officer, Director)inBrent Rice(Chief Commercial Officer)in
BoardJason Zhang(Director)Cong Xu(Director)Stuart Lutzker(Director)
PartnerHongbo Lu· solo GP
Co-investorsCatalio Capital Management, LPForesite CapitalGeneral CatalystHBM Healthcare InvestmentsHBM PartnersHongShan Capital Group+4 more
.png)
ClinChoice operates a network of investigator sites that participate in clinical studies to support drug and device development.
BiotechHealthtechMedical DevicesPhiladelphia, US
Dr. John Balian(CEO)
Co-investorsDFJ DragonFundDraper AssociatesDraper DragonApricot CapitalLegend CapitalSherpa Healthcare Partners
Neukio is a biopharmaceutical company developing iPSC-derived cell technology platforms and next-generation off-the-shelf, mass-producible immune cell products (such as NK cells) to treat solid tumors and autoimmune diseases.
BiotechDeep TechHealthtech
Liqun Wang(Founder)
Co-investorsPan-Lin CapitalAlwin CapitalIDG CapitalSherpa Healthcare Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.